The UK Space Agency has unveiled a coordinated set of measures to support pharmaceutical companies developing medicines in space, aiming to accelerate the growth of in-orbit manufacturing and translate microgravity research into real-world treatments.

Microgravity offers a unique environment that cannot be replicated on Earth and can significantly influence how biologic drugs form and behave. Scientists believe this environment could enhance the quality, stability and effectiveness of complex medicines, potentially improving treatments for conditions such as cancer, rare diseases and other serious illnesses.

To help transform these discoveries into accessible therapies, the UK government has introduced a package of regulatory and industry support measures. The initiative aligns with the country’s Euro 2 billion Life Sciences Sector Plan and aims to create clearer pathways from space-based research to patient access on Earth.

The programme is being led by the UK Space Agency with support from the Medicines and Healthcare products Regulatory Agency, the Regulatory Innovation Office within the Department for Science, Innovation and Technology and the Civil Aviation Authority.

The new framework will provide regulatory guidance, industry case studies, supply-chain engagement and a regulatory sandbox designed to help companies test and develop space-manufactured pharmaceutical products. These steps are expected to reduce uncertainty for companies and investors while accelerating commercial development.

UK Space Minister Liz Lloyd said the initiative aims to remove barriers that have previously slowed the commercialisation of in-orbit manufacturing, including regulatory uncertainties and supply-chain challenges.

David Willetts, Chair of the UK Space Agency and the Regulatory Innovation Office, highlighted the economic and healthcare potential of combining the country’s strong space industry with its life sciences sector. He noted that establishing clear regulatory pathways will give innovators and investors confidence to bring space-enabled medicines to market.

The UK government has identified in-orbit servicing, assembly and manufacturing as priority capabilities for national growth and technological leadership. Recent demonstration missions such as ForgeStar-1 by Space Forge and ELSA-D by Astroscale UK have already showcased the country’s ability to license and support innovative space technologies.

Further investment is also supporting early-stage research projects. For example, the agency recently funded a Euro 250,000 feasibility study for BioOrbit, a start-up exploring scalable systems to crystallise biologic medicines in microgravity, which could help enable at-home cancer treatments.

To further encourage innovation, regulators are developing new guidance, launching a re-entry regulatory sandbox and working to streamline licensing procedures for frequent in-orbit missions.

According to Rosemary Whitbread, Head of Space Regulation Policy at the Civil Aviation Authority, manufacturing products in space can unlock advanced technologies that are impossible to produce on Earth. She noted that the UK’s existing regulatory framework can already support such activities provided companies follow established approval processes.

Meanwhile, the Medicines and Healthcare products Regulatory Agency is preparing principles-based case studies and regulatory pathways to guide biotechnology and pharmaceutical companies through the process of bringing space-manufactured medicines to market.

MHRA Chief Executive Lawrence Tallon said the agency is committed to ensuring that regulatory systems remain adaptable for emerging manufacturing approaches, including those involving microgravity and modular production systems.

Industry leaders have welcomed the government’s initiative. Katie King, CEO of BioOrbit, said the move signals the UK’s ambition to lead in space-enabled healthcare innovation. She added that the support will help build a stronger pipeline of new treatments while driving investment, jobs and technological leadership.

Through these initiatives, the UK government hopes to ensure that breakthroughs achieved in orbit ultimately lead to safer, more effective medicines and improved healthcare outcomes for patients on Earth.